Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients

13:00 EDT 19 Sep 2018 | ISAAA

The first human trial in the U.S. using CRISPR gene-editing technology will soon be launched by Vertex Pharmaceuticals and CRISPR Therapeutics. The developers will conduct the trial to evaluate CTX001, a stem cell therapy developed using CRISPR to treat patients with beta thalassemia, a blood disorder characterized by low levels of hemoglobin which...

Original Article: Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients


More From BioPortfolio on "Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...